SOUTH SAN FRANCISCO, Calif. – 30 October 2019 – Twist Bioscience Corporation (NASDAQ:TWST), a leading provider of high-quality synthetic DNA, and MGI International Sales Co., Limited (MGI) today announced a co-marketing agreement for Twist Bioscience’s target enrichment product line in Europe and Asia Pacific.
Under the non-exclusive agreement, MGI will make Twist catalog and custom products available on its platform, including the Twist Human Core Exome Kit, Twist Custom Panels, Twist Mouse Exome, Twist RefSeq, Twist Universal Blockers, and Twist Fast Hybridization and Wash Kit—each specifically formatted to work with MGI’s DNBSEQ™ sequencers.
“This agreement brings together our best-in-class target enrichment products and MGI’s cost-effective, PCR-free sequencing solutions, creating a combined platform to address growing markets in Europe and Asia Pacific,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “It expands our geographic footprint and provides MGI’s customers with exceptional enrichment uniformity, custom panel enablement, and optimal performance.”
Duncan Yu, president of MGI, added, “This collaboration leverages the strengths of both companies and extends our sequencing technology for customers in cancer, neurology, autoimmune disease, and other genomic applications. We look forward to expanding our offerings with leading products like the Twist target enrichment package, fully compatible with the DNBSEQ platform.”
